Physicians’ perceptions of occupational stress at individual level were shaped by stressors within and across four levels
Severe Outcomes From COVID-19 Up With Preexisting Neuropsych Conditions
Neuropsychiatric conditions and/or associated treatment linked to increased risk for severe outcomes from COVID-19, SARIs
Cardiac Risk Counseling Advised Before Monkeypox Vaccination
A recent non-peer-reviewed study based on Kaiser Permanente Northwest (KPNW) data intended to document any cardiac events associated with Bavarian Nordic's two-dose JYNNEOS® vaccine.
Since May 2022, about 600,000 people have received one or more vaccine doses in the U.S.
And New York City began offering people second doses of JYNNEOS in September 2022.
Immunologically, Hybrid Immunity Makes Sense
It is becoming clear that hybrid immunity, the immunity provided by a combination of infection and vaccination, offers better protection with diverse antibodies against subsequent COVID-19 infection than vaccination or infection alone, wrote a recent editorial published by The Lancet Infectious Diseases.
However, the real-world immunity picture is very complex.
Telehealth Ups Engagement for Medicaid Patients With Mental Health Diagnosis
However, overall, mental health visits were down at federally qualified health centers during the pandemic
Adverse Events Mild, Rare With mAb Treatment for COVID-19 in Pregnancy
No differences seen in any obstetric-associated outcome or in composite 28-day COVID-19 outcome
SARS-CoV-2 Reinfection Ups Risks for Death, Hospitalization
Risks were increased, regardless of vaccination status, and increased according to number of reinfections
Hospitalizations Up Among Infants Younger Than 6 Months During Omicron
No increase seen in prevalence of indicators of severe disease among these hospitalized infants
Antibody Against SARS-CoV-2 Joined Best Inventions of 2022
AstraZeneca recently announced its long-acting monoclonal antibody (mAbs) was recently added to the list of Best Inventions of 2022 by TIME.
EVUSHELD™ is the first and only long-acting mAbs to receive authorization in the U.S. to prevent COVID-19 in immunocompromised people.
"Immunocompromised individuals have lived a very different pandemic experience than most of us," said Joris Silon, U.S. Country President, BioPharmaceutical Business Unit, AstraZeneca, in a press release on November 10, 2022.
America’s Emergency Physicians Warn of Surge in Patients Due to ‘Tripledemic’
A coalition of health and medical groups has called on the White House to hold a summit on ongoing problems facing U.S. emergency departments